Novartis jumps into the KRAS race with a positive early snapshot — and a full slate of trials planned for ambitious bid to unseat Amgen

NEW ORLEANS — Amgen may have won the race to first approval among the KRAS G12C rivals, but that hasn’t deterred Novartis from unveiling an all-hands clinical campaign to get a best-of-class rival onto the market. Novartis tipped its hand at AACR22, highlighting early data on JDQ443 that demonstrated a…

...

Click to view original post